Ultrasensitive Detection

With its ultrasensitivity, the SAGA technology platforms open up unique possibilities in the analysis of cancers that can be deployed and run in your own molecular laboratory. SAGA enables a wide range of research-oriented and clinical applications. Whether the purpose is to find patients with specific mutations, monitor therapeutic effect, measure residual disease, or detect relapses, SAGA has the most informative method currently available. The assay kits work equally well with liquid biopsies or tissue biopsies.

A new window of possibility

The SAGAsafe® technology is based on droplet digital PCR and can reliably detect and quantify mutations to ~0.001% mutant allele frequency (MAF), the new standard of ultrasensitivity. The implications of the improved sensitivity/specificity are that a new window of possibility is opened to identify the patients carrying tissue and ctDNA mutations below 0.1% MAF. For example, in patient plasma samples our kits have identified numerous potentially actionable EGFR T790M resistance mutations at MAFs down to 0.003%.

Run our kits

With our over 250 assays in our catalog, we can train, assist, and support the launch of SAGAsafe® assays in your laboratory. Assays may be used to:

  • Identify tumors with targetable mutations
  • Monitor minimal residual disease (MRD)
  • Monitor therapeutic response
  • Detect resistance mutations
  • Recurrence monitoring


We launched our first CE-IVD marked SAGAsafe® kit for EGFR T790M in Q4 2020, and will be broadening our portfolio of regulatory-approved assays in 2021 and beyond.


SAGA has developed and validated more than 250 different assays to date, covering most of the mutations of clinical interest. Additionally, assays can be multiplexed to include up to a dozen different mutations in the same run.

Custom assays can be developed within a few weeks. A selection of these assays has been further validated in clinical research and, by hospital laboratories, for clinical diagnostic use.

We offer our partners and customers to utilize our kits in their own laboratory or the laboratory of their choosing. We offer training and advice as required.  


SAGA is currently involved in a wide range of research-oriented studies in breast cancer, prostate cancer, lung cancer, ovarian cancer, melanoma, colorectal cancer, and AML. An increasing number of hospitals are using our tests clinically based on internal laboratory validation.

What our customers say

For lung cancer patients treated with EGFR TKIs, resistance mutations are a big problem and in order to detect those mutations effectively in both tissue and plasma samples you need an assay with very high sensitivity as well as specificity. After benchmarking, we determined SAGA’s tests offered the highest sensitivity to identify more samples with mutations. We’re happy to be entering this partnership.
Gisela Helenius, Department of Laboratory Medicine, University Hospital Örebro